Catalent takes over Paragon Bioservices

Note: This section contains information in English only.
Source: Dukascopy Bank SA
The drug developer Catalent is set to acquire the privately-owned, gene-therapy oriented Paragon Bioservices in a deal valued at $1.2B, according to the Wall Street Journal's report on Sunday.

Actual Topics